BioSpace News Archive

ASIT Biotech today announces its annual results for the year 2017, prepared in accordance with the IFRS standards adopted by the European Union, as well as its recent clinical developments and 2018 outlook.

Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy.

The company issued the statement in response to a motion filed by the Office of the Maryland Attorney General:

The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee’s employment commencement date with the Company.

Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.

Invitae today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

Kadmon today announced topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib.

For the 2017 fourth quarter, the company reported net sales of $22.2 million, up 25.2 percent from $17.7 million in the prior-year period.

This move will allow the company to better optimize its wheelchair manufacturing facility in France.

The clinical research teams and business leaders from both the Dallas and Phoenix centers will be attending the 2018 American Academy of Dermatology Annual Meeting from February 16 through 20 at the San Diego Convention Center.